FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W41337129> ?p ?o ?g. }

• W41337129 endingPage "28" @default.
• W41337129 startingPage "22" @default.
• W41337129 abstract "No AccessJournal of Urology1 Jan 1989Superficial Bladder Cancer Treated with Bacillus Calmette-Guerin: A Multivariate Analysis of Factors Affecting Tumor Progression Harry W. Herr, Robert A. Badalament, David A. Amato, Vincent P. Laudone, William R. Fair, and Willet F. Whitmore Harry W. HerrHarry W. Herr More articles by this author , Robert A. BadalamentRobert A. Badalament More articles by this author , David A. AmatoDavid A. Amato More articles by this author , Vincent P. LaudoneVincent P. Laudone More articles by this author , William R. FairWilliam R. Fair More articles by this author , and Willet F. WhitmoreWillet F. Whitmore More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)40575-1AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail A multivariate analysis was performed on data from 221 patients with superficial bladder tumors (papilloma in 30, grade II to III stage Ta in 51, grade II to III stage Tis in 111 and grade II to III stage T1 in 29) who were treated with intravesical bacillus Calmette-Guerin and followed for a minimum of 24 months or until progression. The purpose of this analysis was to identify prognostic variables predictive of tumor progression defined as muscle invasion, metastasis or endoscopically uncontrolled superficial bladder carcinoma involving the bladder and/or prostatic urethra. Variables examined before bacillus Calmette-Guerin, and at 3 and 6 months after bacillus Calmette-Guerin included age, sex, race, purified protein derivative reaction, duration of disease, tumor category, tumor grade, multifocality, results of cytology, flow cytometry, cystoscopy, biopsy, prior chemotherapy and bacillus C almette-Guerin treatment regimen. Significant variables (Cox regression analysis, p less than 0.07) for tumor progression were before bacillus Calmette-Guerin—stage T1 tumors and duration of disease less than 1 year, at 3 months after bacillus Calmette-Guerin—stage T1 tumor, duration of disease less than 1 year, positive cytology studies and multifocality, and at 6 months after bacillus Calmette-Guerin—stage T1 tumor, positive cytology and positive biopsy other than stage T1 tumors. Prognostic risk groups were best defined at 6 months after bacillus Calmette-Guerin, the probability of tumor progression thereafter being at 1, 3 and 5 years, respectively, as follows: for risk group 1 (T1 tumor)—71, 100 and 100 per cent, for risk group 2 (positive biopsy other than T1 plus positive cytology)—25, 79 and 100 per cent, for risk group 3 (either positive biopsy other than stage T1 or positive cytology studies)— 18, 40 and greater than 81 per cent, and for risk group 4 (negative biopsy and negative cytology studies)— 2,11 and 26 per cent, respectively. Evaluation of patients with superficial bladder carcinoma at 6 months after intravesical bacillus Calmette-Guerin therapy identifies the probability of tumor progression. Patients at high risk for tumor progression require alternative treatment strategies, whereas low risk patients can be observed for further therapy if necessary. © 1989 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByRosevear H, Lightfoot A, Birusingh K, Maymí J, Nepple K and O'Donnell M (2018) Factors Affecting Response to Bacillus Calmette-Guérin Plus Interferon for Urothelial Carcinoma in SituJournal of Urology, VOL. 186, NO. 3, (817-823), Online publication date: 1-Sep-2011.Morales A, Phadke K and Steinhoff G (2018) Intravesical Mycobacterial Cell Wall-DNA Complex in the Treatment of Carcinoma In Situ of the Bladder After Standard Intravesical Therapy Has FailedJournal of Urology, VOL. 181, NO. 3, (1040-1045), Online publication date: 1-Mar-2009.HERR H (2018) RESTAGING TRANSURETHRAL RESECTION OF HIGH RISK SUPERFICIAL BLADDER CANCER IMPROVES THE INITIAL RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPYJournal of Urology, VOL. 174, NO. 6, (2134-2137), Online publication date: 1-Dec-2005.HERR H and DALBAGNI G (2018) Defining Bacillus Calmette-Guerin Refractory Superficial Bladder TumorsJournal of Urology, VOL. 169, NO. 5, (1706-1708), Online publication date: 1-May-2003.Soloway M, Sofer M and Vaidya A (2018) Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, VOL. 167, NO. 4, (1573-1583), Online publication date: 1-Apr-2002.SAINT F, PATARD J, MAILLE P, SOYEUX P, HOZNEK A, SALOMON L, ABBOU C and CHOPIN D (2018) PROGNOSTIC VALUE OF A T HELPER 1 URINARY CYTOKINE RESPONSE AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN TREATMENT FOR SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 167, NO. 1, (364-367), Online publication date: 1-Jan-2002.HERR H and SOGANI P (2018) DOES EARLY CYSTECTOMY IMPROVE THE SURVIVAL OF PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER TUMORS?Journal of Urology, VOL. 166, NO. 4, (1296-1299), Online publication date: 1-Oct-2001.KIM J and STEINBERG G (2018) THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 165, NO. 3, (745-756), Online publication date: 1-Mar-2001.SAINT F, PATARD J, MAILLE P, SOYEUX P, HOZNEK A, SALOMON L, DE LA TAILLE A, ABBOU C and CHOPIN D (2018) T HELPER 1/2 LYMPHOCYTE URINARY CYTOKINE PROFILES IN RESPONDING AND NONRESPONDING PATIENTS AFTER 1 AND 2 COURSES OF BACILLUS CALMETTE-GUERIN FOR SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 166, NO. 6, (2142-2147), Online publication date: 1-Dec-2001.O’DONNELL M, KROHN J and DeWOLF W (2018) SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-α2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILEDJournal of Urology, VOL. 166, NO. 4, (1300-1305), Online publication date: 1-Oct-2001.MILLÁN-RODRÍGUEZ F, CHÉCHILE-TONIOLO G, SALVADOR-BAYARRI J, PALOU J, ALGABA F and VICENTE-RODRÍGUEZ J (2018) PRIMARY SUPERFICIAL BLADDER CANCER RISK GROUPS ACCORDING TO PROGRESSION, MORTALITY AND RECURRENCEJournal of Urology, VOL. 164, NO. 3 Part 1, (680-684), Online publication date: 1-Sep-2000.SOLSONA E, IBORRA I, DUMONT R, RUBIO-BRIONES J, CASANOVA J and ALMENAR S (2018) THE 3-MONTH CLINICAL RESPONSE TO INTRAVESICAL THERAPY AS A PREDICTIVE FACTOR FOR PROGRESSION IN PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 164, NO. 3 Part 1, (685-689), Online publication date: 1-Sep-2000.MILLÁN-RODRÍGUEZ F, CHÉCHILE-TONIOLO G, SALVADOR-BAYARRI J, PALOU J and VICENTE-RODRÍGUEZ J (2018) MULTIVARIATE ANALYSIS OF THE PROGNOSTIC FACTORS OF PRIMARY SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 163, NO. 1, (73-78), Online publication date: 1-Jan-2000.HERR H and DONAT S (2018) PROSTATIC TUMOR RELAPSE IN PATIENTS WITH SUPERFICIAL BLADDER TUMORS: 15-YEAR OUTCOMEJournal of Urology, VOL. 161, NO. 6, (1854-1857), Online publication date: 1-Jun-1999.DALBAGNI G, RECHTSCHAFFEN T and HERR H (2018) IS TRANSURETHRAL BIOPSY OF THE BLADDER NECESSARY AFTER 3 MONTHS TO EVALUATE RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPY?Journal of Urology, VOL. 162, NO. 3 Part 1, (708-709), Online publication date: 1-Sep-1999.DINNEY C, BABKOWSKI R, ANTELO M, PERROTTE P, LIEBERT M, ZHANG H, PALMER J, VELTRI R, KATZ R and GROSSMAN H (2018) RELATIONSHIP AMONG CYSTECTOMY, MICROVESSEL DENSITY AND PROGNOSIS IN STAGE T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDERJournal of Urology, VOL. 160, NO. 4, (1285-1290), Online publication date: 1-Oct-1998.Narayan P (2018) Editorial: Transitional Cell CarcinomaJournal of Urology, VOL. 156, NO. 2, (389-390), Online publication date: 1-Aug-1996.Messing E, Young T, Hunt V, Newton M, Bram L, Vaillancourt A, Hisgen W, Greenberg E, Kuglitsch M and Wegenke J (2018) Hematuria Home Screening: Repeat Testing ResultsJournal of Urology, VOL. 154, NO. 1, (57-61), Online publication date: 1-Jul-1995.Hudson M and Herr H (2018) Carcinoma in Situ of the BladderJournal of Urology, VOL. 153, NO. 3, (564-572), Online publication date: 1-Mar-1995.Kamat M, Kulkarni J, Tongaonkar H and Dalal A (2018) Intravesical Bacillus Calmette-Guerin For Superficial Bladder Cancer: Experience With Danish 1331 StrainJournal of Urology, VOL. 152, NO. 5 Part 1, (1424-1428), Online publication date: 1-Nov-1994.Droller M (2018) Editorial CommentsJournal of Urology, VOL. 151, NO. 1, (19-19), Online publication date: 1-Jan-1994.Amling C, Thrasher J, Frazier H, Dodge R, Robertson J and Paulson D (2018) Radical Cystectomy for Stages TA, TIS and T1 Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 151, NO. 1, (31-35), Online publication date: 1-Jan-1994.Hawkyard S, Jackson A, Prescott S, James K and Chisholm G (2018) The Effect of Recombinant Cytokines on Bladder Cancer Cells in VitroJournal of Urology, VOL. 150, NO. 2 Part 1, (514-518), Online publication date: 1-Aug-1993.Melekos M, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G and Dauaher H (2018) Intravesical Bacillus Calmette-Guerin Immunoprophylaxis of Superficial Bladder Cancer: Results of a Controlled Prospective Trial with Modified Treatment ScheduleJournal of Urology, VOL. 149, NO. 4, (744-748), Online publication date: 1-Apr-1993.Messing E, Young T, Hunt V, Roecker E, Vaillancourt A, Hisgen W, Greenberg E, Kuglitsch M and Wegenke J (2018) Home Screening for Hematuria: Results of a Multi-Clinic StudyJournal of Urology, VOL. 148, NO. 2 Part 1, (289-292), Online publication date: 1-Aug-1992.Giella J, Ring K, Olsson C, Karp F and Benson M (2018) The Predictive Value of Flow Cytometry and Urinary Cytology in the Followup of Patients with Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 148, NO. 2 Part 1, (293-296), Online publication date: 1-Aug-1992.Cookson M and Sarosdy M (2018) Management of Stage T1 Superficial Bladder Cancer with Intravesical Bacillus Calmette-Guerin TherapyJournal of Urology, VOL. 148, NO. 3 Part 1, (797-801), Online publication date: 1-Sep-1992.Eure G, Cundiff M and Schellhammer P (2018) Bacillus Calmette-Guerin Therapy for High Risk Stage T1 Superficial Bladder CancerJournal of Urology, VOL. 147, NO. 2, (376-379), Online publication date: 1-Feb-1992.Klein E, Rogatko A and Herr H (2018) Management of Local Bacillus Calmette-Guerin Failures in Superficial Bladder CancerJournal of Urology, VOL. 147, NO. 3 Part 1, (601-605), Online publication date: 1-Mar-1992.Hawkyard S, Jackson A, James K, Prescott S, Smyth J and Chisholm G (2018) The Inhibitory Effects of Interferon Gamma on the Growth of Bladder Cancer CellsJournal of Urology, VOL. 147, NO. 5, (1399-1403), Online publication date: 1-May-1992.Kaubisch S, Lum B, Reese J, Freiha F and Torti F (2018) Stage T1 Bladder Cancer: Grade is the Primary Determinant for Risk of Muscle InvasionJournal of Urology, VOL. 146, NO. 1, (28-31), Online publication date: 1-Jul-1991.Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D and Garbeglio A (2018) A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?Journal of Urology, VOL. 146, NO. 1, (32-35), Online publication date: 1-Jul-1991.Herr H (2018) Progression of Stage T1 Bladder Tumors After Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 145, NO. 1, (40-43), Online publication date: 1-Jan-1991.Steinberg G, Brendler C, Squire R and Isaacs J (2018) Experimental Intravesical Therapy for Superficial Transitional Cell Carcinoma in a Rat Bladder Tumor ModelJournal of Urology, VOL. 145, NO. 3, (647-653), Online publication date: 1-Mar-1991.Huland H, Klöppel G, Feddersen I, Otto U, Brachmann W, Hubmann H, Kaufmann J, Knipper W, Lantzius-Beninga F and Huland E (2018) Comparison of Different Schedules of Cytostatic Intravesical Instillations in Patients with Superficial Bladder Carcinoma: Final Evaluation of a Prospective Multicenter Study with 419 PatientsJournal of Urology, VOL. 144, NO. 1, (68-71), Online publication date: 1-Jul-1990.Ratliff T (2018) Editorial CommentsJournal of Urology, VOL. 144, NO. 1, (71-71), Online publication date: 1-Jul-1990.Coplen D, Marcus M, Myers J, Ratliff T and Catalona W (2018) Long-Term Followup of Patients Treated With 1 or 2, 6-Week Courses of Intravesical Bacillus Calmette-Guerin: Analysis of Possible Predictors of Response Free of TumorJournal of Urology, VOL. 144, NO. 3, (652-657), Online publication date: 1-Sep-1990.Hudson M, Yuan J, Catalona W and Ratliff T (2018) Adverse Impact of Fibrin Clot Inhibitors on Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder TumorsJournal of Urology, VOL. 144, NO. 6, (1362-1364), Online publication date: 1-Dec-1990.Bretton P, Herr H, Kimmel M, Whitmore W, Laudone V, Oettgen H and Fair W (2018) The Response of Patients with Superficial Bladder Cancer to a Second Course of Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 143, NO. 4, (710-712), Online publication date: 1-Apr-1990.Ratliff T (2018) Editorial CommentsJournal of Urology, VOL. 143, NO. 4, (712-712), Online publication date: 1-Apr-1990.Soloway M (2018) Editorial CommentsJournal of Urology, VOL. 144, NO. 1, (71-72), Online publication date: 1-Jul-1990.Bretton P, Herr H, Kimmel M, Fair W, Whitmore W and Melamed M (2018) Flow Cytometry as a Predictor of Response and Progression in Patients with Superficial Bladder Cancer Treated with Bacillus Calmette-GuerinJournal of Urology, VOL. 141, NO. 6, (1332-1336), Online publication date: 1-Jun-1989. Volume 141Issue 1January 1989Page: 22-28 Advertisement Copyright & Permissions© 1989 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Harry W. Herr More articles by this author Robert A. Badalament More articles by this author David A. Amato More articles by this author Vincent P. Laudone More articles by this author William R. Fair More articles by this author Willet F. Whitmore More articles by this author Expand All Advertisement PDF DownloadLoading ..." @default.
• W41337129 created "2016-06-24" @default.
• W41337129 creator A5048541532 @default.
• W41337129 creator A5049771578 @default.
• W41337129 creator A5054035174 @default.
• W41337129 creator A5072952391 @default.
• W41337129 creator A5074806728 @default.
• W41337129 creator A5079115182 @default.
• W41337129 date "1989-01-01" @default.
• W41337129 modified "2023-10-14" @default.
• W41337129 title "Superficial Bladder Cancer Treated with Bacillus Calmette-Guerin: A Multivariate Analysis of Factors Affecting Tumor Progression" @default.
• W41337129 cites W1530788902 @default.
• W41337129 cites W1992876565 @default.
• W41337129 cites W2168812605 @default.
• W41337129 cites W2175444778 @default.
• W41337129 cites W2180705936 @default.
• W41337129 cites W2397494303 @default.
• W41337129 cites W2397716653 @default.
• W41337129 cites W2402487223 @default.
• W41337129 cites W2416439358 @default.
• W41337129 cites W2417467146 @default.
• W41337129 cites W2470130076 @default.
• W41337129 cites W4239330499 @default.
• W41337129 cites W4293241248 @default.
• W41337129 cites W94524485 @default.
• W41337129 doi "https://doi.org/10.1016/s0022-5347(17)40575-1" @default.
• W41337129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2908949" @default.
• W41337129 hasPublicationYear "1989" @default.
• W41337129 type Work @default.
• W41337129 sameAs 41337129 @default.
• W41337129 citedByCount "231" @default.
• W41337129 countsByYear W413371292012 @default.
• W41337129 countsByYear W413371292013 @default.
• W41337129 countsByYear W413371292014 @default.
• W41337129 countsByYear W413371292015 @default.
• W41337129 countsByYear W413371292016 @default.
• W41337129 countsByYear W413371292017 @default.
• W41337129 countsByYear W413371292018 @default.
• W41337129 countsByYear W413371292019 @default.
• W41337129 countsByYear W413371292021 @default.
• W41337129 crossrefType "journal-article" @default.
• W41337129 hasAuthorship W41337129A5048541532 @default.
• W41337129 hasAuthorship W41337129A5049771578 @default.
• W41337129 hasAuthorship W41337129A5054035174 @default.
• W41337129 hasAuthorship W41337129A5072952391 @default.
• W41337129 hasAuthorship W41337129A5074806728 @default.
• W41337129 hasAuthorship W41337129A5079115182 @default.
• W41337129 hasConcept C121608353 @default.
• W41337129 hasConcept C126322002 @default.
• W41337129 hasConcept C126894567 @default.
• W41337129 hasConcept C143998085 @default.
• W41337129 hasConcept C2779150676 @default.
• W41337129 hasConcept C2780352672 @default.
• W41337129 hasConcept C2910508445 @default.
• W41337129 hasConcept C2992225637 @default.
• W41337129 hasConcept C38180746 @default.
• W41337129 hasConcept C71924100 @default.
• W41337129 hasConcept C86803240 @default.
• W41337129 hasConcept C89423630 @default.
• W41337129 hasConceptScore W41337129C121608353 @default.
• W41337129 hasConceptScore W41337129C126322002 @default.
• W41337129 hasConceptScore W41337129C126894567 @default.
• W41337129 hasConceptScore W41337129C143998085 @default.
• W41337129 hasConceptScore W41337129C2779150676 @default.
• W41337129 hasConceptScore W41337129C2780352672 @default.
• W41337129 hasConceptScore W41337129C2910508445 @default.
• W41337129 hasConceptScore W41337129C2992225637 @default.
• W41337129 hasConceptScore W41337129C38180746 @default.
• W41337129 hasConceptScore W41337129C71924100 @default.
• W41337129 hasConceptScore W41337129C86803240 @default.
• W41337129 hasConceptScore W41337129C89423630 @default.
• W41337129 hasIssue "1" @default.
• W41337129 hasLocation W413371291 @default.
• W41337129 hasLocation W413371292 @default.
• W41337129 hasOpenAccess W41337129 @default.
• W41337129 hasPrimaryLocation W413371291 @default.
• W41337129 hasRelatedWork W2366691982 @default.
• W41337129 hasRelatedWork W2370208313 @default.
• W41337129 hasRelatedWork W2384311157 @default.
• W41337129 hasRelatedWork W2416261304 @default.
• W41337129 hasRelatedWork W2480000808 @default.
• W41337129 hasRelatedWork W2771908915 @default.
• W41337129 hasRelatedWork W324577642 @default.
• W41337129 hasRelatedWork W41337129 @default.
• W41337129 hasRelatedWork W4205910527 @default.
• W41337129 hasRelatedWork W2118673085 @default.
• W41337129 hasVolume "141" @default.
• W41337129 isParatext "false" @default.
• W41337129 isRetracted "false" @default.
• W41337129 magId "41337129" @default.
• W41337129 workType "article" @default.